Genomic Biomarker-guided Neoadjuvant Therapy for Prostate Cancer (SEGNO) — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Genomic Biomarker-guided Neoadjuvant Therapy for Prostate Cancer (SEGNO) — Stella

Home/Locally Advanced Prostate Cancer/

View on ClinicalTrials.gov

Recruiting

Back to Locally Advanced Prostate Cancer trials

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(1 site)

China

The First Affiliated Hospital of Xiamen University, Xiamen, Fujian

Key details

Phase

Safety & dosing

Sponsor

The First Affiliated Hospital of Xiamen University

Enrollment target

~40 participants

Started

April 2024

Primary completion

April 2026

This trial's estimated completion date has passed — the record may not be fully up to date.

Age range

18 Years and older

Sex

Male only

Last updated April 2024

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.